Company profile RLAY

Relay Therapeutics Inc
relay therapeutics is building the world’s first dedicated drug discovery platform centered on protein motion to discover and develop new medicines that will make a transformative difference for patients. by placing protein motion at the heart of drug discovery, relay is pursuing what it believes will be a fundamental paradigm shift within the pharmaceutical industry, usherin...g in a new generation of drugs with the potential to improve and extend the lives of millions of patients. headquartered in cambridge, mass., relay therapeutics is a private company launched in 2016. to date, relay therapeutics has raised $120m in financing from third rock ventures, bvf partners, gv (formerly google ventures), an affiliate of d.e. shaw research, casdin capital, ecor1 capital, section 32 and alexandria venture investments. our world-class team is equal parts bright and bold, with a shared passion for working in intellectually stimulating environments. if you're creative, collaborative and passionate Show More
Quarter analysis & expected interest

There is not enough data for Relay Therapeutics login to provide analysis

Correlation between past revenue and Relay Therapeutics login search interest

There is not enough data for Relay Therapeutics login to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Relay Therapeutics login to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 09 2024 10:50:54.

After 39 days of this quarter the interest is at 73.0. Based on that we can calculate that during remaining 52 days it will total up to 170.0.
Relay Therapeutics stock expected interest is significantly higher compared to previous quarter (+50.4%) and same quarter last year (+82.8%).

YearQ1Q2Q3Q4
201939
33
-15.4% QoQ
69
109.1% QoQ
21
-69.6% QoQ
2020 19
-51.3% YoY -9.5% QoQ
26
-21.2% YoY 36.8% QoQ
296
329.0% YoY 1038.5% QoQ
64
204.8% YoY -78.4% QoQ
2021 168
784.2% YoY 162.5% QoQ
59
126.9% YoY -64.9% QoQ
57
-80.7% YoY -3.4% QoQ
93
45.3% YoY 63.2% QoQ
2022 52
-69.0% YoY -44.1% QoQ
67
13.6% YoY 28.8% QoQ
168
194.7% YoY 150.7% QoQ
66
-29.0% YoY -60.7% QoQ
2023 93
78.8% YoY 40.9% QoQ
124
85.1% YoY 33.3% QoQ
70
-58.3% YoY -43.5% QoQ
113
71.2% YoY 61.4% QoQ
2024 73
-21.5% YoY -35.4% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Relay Therapeutics stock search interestLast update: February 09 2024 10:50:53.
Correlation coefficient between keyword and revenue is 0.06
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 09 2024 10:50:56.

The average 5 years interest of Relay Therapeutics stock was 6.78 per week.
The last year interest of Relay Therapeutics stock compared to the last 5 years has changed by 24.48%.
This is something to be checked.
The last year interest is quite higher compared to 5 years ago. It has increased by 170.51%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 09 2024 10:51:02.

After 39 days of this quarter the interest is at 61.0. Based on that we can calculate that during remaining 52 days it will total up to 142.0.
Relay Therapeutics news expected interest is significantly higher compared to previous quarter (+46.4%) and same quarter last year (+42.0%).

YearQ1Q2Q3Q4
201922
76
245.5% QoQ
170
123.7% QoQ
27
-84.1% QoQ
2020 23
4.5% YoY -14.8% QoQ
0
-100.0% YoY -100.0% QoQ
75
-55.9% YoY inf% QoQ
65
140.7% YoY -13.3% QoQ
2021 67
191.3% YoY 3.1% QoQ
113
inf% YoY 68.7% QoQ
164
118.7% YoY 45.1% QoQ
118
81.5% YoY -28.0% QoQ
2022 44
-34.3% YoY -62.7% QoQ
189
67.3% YoY 329.5% QoQ
31
-81.1% YoY -83.6% QoQ
30
-74.6% YoY -3.2% QoQ
2023 100
127.3% YoY 233.3% QoQ
23
-87.8% YoY -77.0% QoQ
79
154.8% YoY 243.5% QoQ
97
223.3% YoY 22.8% QoQ
2024 61
-39.0% YoY -37.1% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Relay Therapeutics news search interestLast update: February 09 2024 10:51:01.
Correlation coefficient between keyword and revenue is 0.33
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 09 2024 10:51:05.

The average 5 years interest of Relay Therapeutics news was 6.03 per week.
The last year interest of Relay Therapeutics news compared to the last 5 years has changed by -17.08%.
This is something to be checked.
The last year interest is quite lower compared to 5 years ago. It has decreased by -18.3%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Relay Therapeutics careers to provide analysis

Correlation between past revenue and Relay Therapeutics careers search interest

There is not enough data for Relay Therapeutics careers to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Relay Therapeutics careers to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Relay Therapeutics precision medicines to provide analysis

Correlation between past revenue and Relay Therapeutics precision medicines search interest

There is not enough data for Relay Therapeutics precision medicines to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Relay Therapeutics precision medicines to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for RLY-4008 clinical trial to provide analysis

Correlation between past revenue and RLY-4008 clinical trial search interest

There is not enough data for RLY-4008 clinical trial to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for RLY-4008 clinical trial to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for RLY-2608 mutant-PI3Ka inhibitor to provide analysis

Correlation between past revenue and RLY-2608 mutant-PI3Ka inhibitor search interest

There is not enough data for RLY-2608 mutant-PI3Ka inhibitor to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for RLY-2608 mutant-PI3Ka inhibitor to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for GDC-1971 Phase 1 trial to provide analysis

Correlation between past revenue and GDC-1971 Phase 1 trial search interest

There is not enough data for GDC-1971 Phase 1 trial to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for GDC-1971 Phase 1 trial to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Relay Therapeutics precision medicine discovery to provide analysis

Correlation between past revenue and Relay Therapeutics precision medicine discovery search interest

There is not enough data for Relay Therapeutics precision medicine discovery to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Relay Therapeutics precision medicine discovery to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for RLAY
Earnings date: 2024-02-22 After close
Company name: Relay Therapeutics Inc
Sector: Manufacturing
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2026-05-05T20:05:00Z

GlobeNewswire
Relay Therapeutics Reports First Quarter 2026 Financial Results and Corporate Updates

2026-04-29T20:05:00Z

GlobeNewswire
Relay Therapeutics to Announce First Quarter 2026 Financial Results and Corporate Highlights on May 5, 2026

2026-04-29T10:42:20Z

Analyst Upgrades
HC Wainwright & Co. Maintains Buy on Relay Therapeutics, Raises Price Target to $25

2026-04-28T16:10:09Z

Analyst Upgrades
Goldman Sachs Maintains Buy on Relay Therapeutics, Raises Price Target to $22

2026-04-28T14:03:50Z

Analyst Upgrades
Citizens Maintains Market Outperform on Relay Therapeutics, Raises Price Target to $19

2026-04-28T13:42:22Z

Analyst Upgrades
Wells Fargo Maintains Overweight on Relay Therapeutics, Raises Price Target to $21

2026-04-28T12:45:30Z

Analyst Upgrades
Oppenheimer Maintains Outperform on Relay Therapeutics, Raises Price Target to $18

2026-04-27T10:00:00Z

GlobeNewswire
Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer

2026-04-14T12:03:25Z

Analyst Upgrades
Jones Trading Initiates Coverage On Relay Therapeutics with Hold Rating, Announces Price Target of $18

2026-04-08T16:38:22Z

Analyst Upgrades
Barclays Maintains Overweight on Relay Therapeutics, Raises Price Target to $21

2026-04-02T20:05:00Z

GlobeNewswire
Relay Therapeutics to Present Initial Clinical Data on Zovegalisib in Vascular Anomalies at the International Society for the Study of Vascular Anomalies World Congress 2026

2026-03-23T11:15:41Z

Analyst Upgrades
HC Wainwright & Co. Maintains Buy on Relay Therapeutics, Raises Price Target to $19

2026-03-17T13:29:41Z

Analyst Upgrades
Citizens Maintains Market Outperform on Relay Therapeutics, Raises Price Target to $17

2026-03-17T13:11:00Z

Analyst Upgrades
Wells Fargo Maintains Overweight on Relay Therapeutics, Raises Price Target to $17

2026-03-16T11:00:00Z

GlobeNewswire
Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026